NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Last Close
Jun 30 04:00PM ET
8.00
Dollar change
-0.43
Percentage change
-5.10
%
IndexRUT P/E- EPS (ttm)-19.25 Insider Own47.85% Shs Outstand16.50M Perf Week7.53%
Market Cap132.29M Forward P/E- EPS next Y-4.23 Insider Trans0.00% Shs Float8.62M Perf Month7.49%
Enterprise Value-43.16M PEG- EPS next Q-0.75 Inst Own51.92% Short Float8.69% Perf Quarter-18.03%
Income-116.51M P/S- EPS this Y87.35% Inst Trans- Short Ratio6.47 Perf Half Y-42.20%
Sales0.00M P/B0.74 EPS next Y-31.01% ROA-67.86% Short Interest0.75M Perf YTD-36.71%
Book/sh10.75 P/C0.74 EPS next 5Y46.70% ROE-75.60% 52W High30.60 -73.86% Perf Year-67.21%
Cash/sh10.84 P/FCF- EPS past 3/5Y-8.04% -10.10% ROIC-65.13% 52W Low5.67 41.21% Perf 3Y-94.82%
Dividend Est.- EV/EBITDA- Sales past 3/5Y- - Gross Margin- Volatility13.56% 9.97% Perf 5Y-96.96%
Dividend TTM- EV/Sales- EPS Y/Y TTM21.69% Oper. Margin- ATR (14)0.92 Perf 10Y-
Dividend Ex-Date- Quick Ratio21.11 Sales Y/Y TTM- Profit Margin- RSI (14)48.61 Recom2.20
Dividend Gr. 3/5Y- - Current Ratio21.11 EPS Q/Q89.92% SMA20-4.96% Beta-0.08 Target Price32.00
Payout- Debt/Eq0.02 Sales Q/Q- SMA505.33% Rel Volume0.61 Prev Close8.43
Employees68 LT Debt/Eq0.01 EarningsMay 08 BMO SMA200-23.28% Avg Volume115.81K Price8.00
IPOOct 31, 2019 Option/ShortYes / Yes EPS/Sales Surpr.41.22% - Trades Volume71,209 Change-5.10%
Date Action Analyst Rating Change Price Target Change
May-22-25Resumed H.C. Wainwright Buy $6
Dec-26-24Upgrade H.C. Wainwright Neutral → Buy $10
Nov-13-24Downgrade Stifel Buy → Hold $7 → $2
Nov-11-24Downgrade Piper Sandler Overweight → Neutral $8 → $2
Nov-11-24Downgrade JP Morgan Neutral → Underweight
May-14-24Downgrade Wolfe Research Outperform → Peer Perform
May-10-24Downgrade Guggenheim Buy → Neutral
May-10-24Downgrade Barclays Overweight → Equal Weight $13 → $4
Feb-22-24Downgrade UBS Buy → Neutral $61 → $10
Feb-21-24Downgrade Leerink Partners Outperform → Market Perform $42 → $10
Jun-23-25 08:00AM
Jun-18-25 09:55AM
Jun-14-25 09:05AM
Jun-13-25 09:00AM
Jun-04-25 04:05PM
12:00PM Loading…
May-16-25 12:00PM
May-08-25 08:00AM
Apr-15-25 08:00AM
Mar-07-25 04:30PM
Mar-06-25 08:00AM
Feb-18-25 06:29AM
Feb-10-25 12:00PM
Jan-09-25 08:00AM
Jan-06-25 08:00AM
Dec-27-24 06:10AM
09:35AM Loading…
Dec-26-24 09:35AM
Dec-24-24 06:44AM
Dec-23-24 01:00PM
07:10AM
07:00AM
Nov-12-24 08:00AM
Nov-11-24 12:18PM
08:00AM
Sep-29-24 07:57AM
Sep-25-24 11:34AM
Aug-08-24 08:00AM
Jun-21-24 01:13AM
Jun-14-24 09:35AM
May-29-24 09:35AM
May-14-24 07:08AM
09:35AM Loading…
May-13-24 09:35AM
May-10-24 03:46PM
07:55AM
07:54AM
May-09-24 04:12PM
03:59PM
02:31PM
01:53PM
08:00AM
Apr-09-24 12:00PM
06:31AM
Mar-22-24 05:39AM
Mar-07-24 02:52PM
08:36AM
08:00AM
Mar-05-24 04:30PM
Feb-20-24 04:03PM
11:22AM
07:58AM
07:39AM
07:30AM
07:17AM
Feb-13-24 08:00AM
Jan-31-24 08:00AM
Jan-02-24 08:00AM
Nov-27-23 08:00AM
Nov-14-23 07:41PM
Nov-13-23 08:00AM
Nov-03-23 12:00PM
Nov-01-23 04:05PM
Oct-18-23 09:00AM
Sep-27-23 09:24PM
Sep-14-23 09:44AM
Aug-30-23 04:05PM
Aug-16-23 09:55AM
Aug-11-23 08:00AM
Aug-09-23 10:26AM
Aug-08-23 06:03AM
Jun-07-23 08:00AM
May-25-23 05:00PM
May-11-23 08:00AM
May-03-23 08:00AM
Apr-26-23 04:19PM
Mar-29-23 08:00AM
Mar-21-23 08:50AM
Mar-14-23 08:00AM
Mar-02-23 10:00AM
Feb-28-23 08:00AM
Feb-27-23 09:55AM
Feb-23-23 08:50AM
Feb-22-23 06:31AM
Feb-16-23 04:02AM
Feb-10-23 09:55AM
Feb-07-23 08:00AM
Jan-31-23 05:43PM
Jan-25-23 08:50AM
Jan-03-23 08:00AM
Dec-30-22 09:55AM
Dec-17-22 08:56AM
Dec-08-22 06:30AM
Nov-30-22 07:05PM
Nov-22-22 08:46AM
Nov-17-22 09:38PM
04:24PM
09:55AM
Nov-12-22 07:42AM
Nov-10-22 09:15AM
08:00AM
Nov-09-22 08:00AM
Oct-12-22 07:50AM
Rapt Therapeutics, Inc. operates as a clinical stage immunology-based biopharmaceutical company, which engages in the discovery, development, and commercialization of oral small molecule therapies for patients in oncology and inflammatory diseases. The company was founded in 2015 and is headquartered in South San Francisco, CA.